Bladder Cancer Pathways
(Urothelial)

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __0a __0is __ I __ II __III __IV __Recurrent

Line of Treatment: __Neoadjuvant/Pre-Op __ Adjuvant/Post-Op __First Line __Second Line __Third Line __Third Line+ __ Maintenance

Goal of Treatment: __Curative __Non-Curative

ECOG Performance Status: __ 0__ 1 __2 __3 __4

Biomarker:

Platinum Resistant/Refractory? __ Yes __ No

Neoadjuvant Therapy | Clinical Stage II, III, or Stage IV without evidence of metastases (cT2, cT3, cT4a, cT4b)

__**CMV**: cisplatin (Platinol), methotrexate and vinblastine (Velban) with leucovorin

__**ddMVAC**: dose dense methotrexate, vinblastine (Velban), doxorubicin (Adriamycin) and cisplatin (Platinol)

__Gemcitabine (Gemzar) and cisplatin (Platinol)

Inreavesical Initial Therapy | Stage I or II after TURBT or following resection of recurrent or persistent disease

__**BCG**: bacillus calmette-guerin intravesical

__Mitomycin C intravesical

Metastatic Disease | First Line Therapy

__Gemcitabine (Gemzar) and cisplatin (Platinol)

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Breast Cancer Pathways:
Neoadjuvant

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __0 __IA __IB __IIA __IIB __IIIA __IIIB __IIIC __IV __Recurrent

Line of Treatment: __Neoadjuvant/Pre-Op __ Adjuvant/Post-Op

ECOG Performance Status: __ 0__ 1 __2 __3 __4

Biomarker:

Estrogen Receptor: __Positive __Negative

Progesterone Receptor: __Positive __Negative

HER2 status: __Positive __Negative by __IHC __FISH

Menopausal Status: Pre / Peri / Post / NA (patient is male)

OncotypeDx**:** __Low* __Intermediate __High __Not Done/Not Reported

Neoadjuvant Therapy | HER2 Negative

__ **AC → weekly T**: doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (every 3 weeks) followed by weekly paclitaxel (Taxol)

__ **ddAC → weekly T**: dose dense doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) followed by weekly paclitaxel (Taxol)

__ **TC**: docetaxel (Taxotere) and cyclophosphamide (Cytoxan)

Neoadjuvant Therapy | HER2 Positive

__ **AC →TH**: doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) followed by paclitaxel (Taxol) and trastuzumab (Herceptin)

__ **TCH**: docetaxel (Taxotere), carboplatin (Paraplatin) and trastuzumab (Herceptin)

Neoadjuvant Therapy | HER2 Positive | Hormone receptor (ER/PR) negative

__ **TCH+P**: docetaxel (Taxotere), carboplatin (Paraplatin), trastuzumab (Herceptin) and pertuzumab (Perjeta)

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Breast Cancer Pathways:
Adjuvant

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __0 __IA __IB __IIA __IIB __IIIA __IIIB __IIIC __IV __Recurrent

Line of Treatment: __Neoadjuvant/Pre-Op __ Adjuvant/Post-Op

ECOG Performance Status: __ 0__ 1 __2 __3 __4

Biomarker:

Estrogen Receptor: __Positive __Negative

Progesterone Receptor: __Positive __Negative

HER2 status: __Positive __Negative by __IHC __FISH

Menopausal Status: Pre / Peri / Post / NA (patient is male)

OncotypeDx**:** __Low* __Intermediate __High __Not Done/Not Reported

Adjuvant Therapy | HER2 Negative*

__ **AC → weekly T**: doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (every 3 weeks) followed by weekly paclitaxel (Taxol)

__ **ddAC → weekly T**: dose dense doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) followed by weekly paclitaxel (Taxol)

__ **TC**: docetaxel (Taxotere) and cyclophosphamide (Cytoxan)

Adjuvant Therapy | HER2 Positive

__ **AC → TH**: doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) followed by paclitaxel (Taxol) and trastuzumab (Herceptin)

__ **TCH**: docetaxel (Taxotere), carboplatin (Paraplatin) and trastuzumab (Herceptin)

__ **TH**: paclitaxel (Taxol) and trastuzumab (Herceptin) **(Pathway for stage I HER2+ breast cancer only)**

*Adjuvant chemotherapy pathways do NOT apply to individuals with Hormone-Receptor positive, lymph node negative, OncotypeDX™ LOW risk score

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Breast Cancer Pathways: Advanced/Metastatic Disease

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __0 __IA __IB __IIA __IIB __IIIA __IIIB __IIIC __IV __Recurrent

Line of Treatment: __First Line __Second Line __Third Line __Third Line +

Estrogen Receptor: __Positive __Negative

Progesterone Receptor: __Positive __Negative

HER2 status: __Positive __Negative by __IHC __FISH

Menopausal Status: Pre / Peri / Post / NA (patient is male)

Metastatic disease | HER2 Negative | First and subsequent lines of therapy (1st line+)

__ Capecitabine (Xeloda)
__ Doxorubicin (Adriamycin)
__ Gemcitabine (Gemzar)
__ Paclitaxel (Taxol)
__ Vinorelbine (Navelbine)

Metastatic disease | HER2 Positive | First line of therapy (1st line)

__ Capecitabine (Xeloda) and trastuzumab (Herceptin)
__ Gemcitabine (Gemzar) and trastuzumab (Herceptin)
__ Paclitaxel (Taxol) and trastuzumab (Herceptin)
__ Pertuzumab (Perjeta), trastuzumab (Herceptin), and docetaxel (Taxotere)
__ Pertuzumab (Perjeta), trastuzumab (Herceptin), and paclitaxel (Taxol)
__ Vinorelbine (Navelbine) and trastuzumab (Herceptin)

Metastatic disease | HER2 Positive | Second and subsequent lines of therapy (2nd line +)

__ Ado-trastuzumab emtansine (Kadcyla)
__ Capecitabine (Xeloda) and lapatinib (Tykerb)
__ Capecitabine (Xeloda) and trastuzumab (Herceptin)
__ Gemcitabine (Gemzar) and trastuzumab (Herceptin)
__ Paclitaxel (Taxol) and trastuzumab (Herceptin)
__ Pertuzumab (Perjeta), trastuzumab (Herceptin), and docetaxel (Taxotere)
__ Pertuzumab (Perjeta), trastuzumab (Herceptin), and paclitaxel (Taxol)
__ Trastuzumab (Herceptin) and lapatinib (Tykerb)
__ Trastuzumab (Herceptin) monotherapy
__ Vinorelbine (Navelbine) and trastuzumab (Herceptin)

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Breast Cancer Pathways:
Endocrine Therapy for Recurrent or Metastatic Disease

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __0 __IA __IB __IIA __IIB __IIIA __IIIB __IIIC __IV __Recurrent

Line of Treatment: __First Line __Second Line __Third Line __Third Line+

Biomarkers:

Estrogen Receptor (ER): __Positive __Negative

Progesterone Receptor (PR)**:** __Positive __Negative

HER2 status: __Positive __Negative by __ IHC __FISH

Menopausal Status**:** Pre / Peri / Post / NA (patient is male)

- Pre-menopausal only: Include ovarian suppression: Yes/No/Unknown

First line therapy (1st line) | Recurrent or Metastatic Disease | Hormone receptor positive

__ Anastrozole (Arimidex)*

__ Fulvestrant, high dose (Faslodex)*

__ Letrozole (Femara)*

__ Letrozole (Femara) and palbociclib (Ibrance)*

__ Tamoxifen**

Second and subsequent lines of therapy (2nd line +) | Recurrent or Metastatic Disease | Hormone receptor positive

__ Anastrozole (Arimidex)*

__ Exemestane (Aromasin)*

__ Fulvestrant, high dose* (Faslodex)

__ Fulvestrant (Faslodex) and palbociclib* (Ibrance)

__ Letrozole (Femara)*

__ Tamoxifen**

First and subsequent lines of therapy (1st line +) | Recurrent or Metastatic Disease | Hormone receptor positive | HER2 positive

__ Anastrozole (Arimidex) and trastuzumab (Herceptin)*

__ Letrozole (Femara) and trastuzumab (Herceptin)*

*** With ovarian suppression for premenopausal individuals. Ovarian suppression utilizes LHRH agonists given as monthly injections. 3-month depot dosing does not reliably suppress estrogen levels.**

**** Tamoxifen is considered Pathway for premenopausal individuals with or without ovarian suppression**

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Chronic Myelogenous Leukemia (CML) Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __New diagnosis or __Relapse

Line of Treatment: __First Line __Second Line __Third Line __Third Line +

ECOG Performance Status: __0 __1 __2 __3 __4

Biomarkers:

CML Phase: __ Chronic Phase __ Accelerated Phase __ Lymphoid Blast Phase __ Myeloid Blast Phase __ Not Reported

Imatinib resistant or intolerant: __ Yes __ No

Philadelphia chromosome: __ Positive __ Negative

T315I: __ Positive __ Negative

Mutation: ____V299L ___T3151

First line of therapy (1st line)

__ Dasatinib* (Sprycel) **for intermediate or high risk disease**

__ Imatinib (Gleevec)

__ Nilotinib* (Tasigna) **for intermediate or high risk disease**

Second line of therapy (2nd line) | Following treatment failure, suboptimal response† , or intolerance to first line therapy

__ Bosutinib (Bosulif)

__ Dasatinib (Sprycel)

__ Nilotinib (Tasigna)

__ Ponatinib‡ (Iclusig)

Third line of therapy (3rd line)

__ Ponatinib (Iclusig)

---

* For patients with intermediate or high risk disease based on Sokal or Hasford Score:
  - Sokal: Intermediate Risk=0.8-1.2; High Risk>1.2
  - Hasford: Intermediate Risk=781-1480; High Risk>1480

† Defined as lack of complete hematologic response or BCR-ABL1 transcripts > 10% (IS) or lack of partial cytogenetic response on bone marrow cytogenetics.

‡ Pathway option for second line therapy only after failure, suboptimal response, or intolerance of a second generation TKI has been used in the first line setting, or T315I mutation has been identified.

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Colorectal Cancer Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __0 __I __IIA __IIB __IIC __IIIA __IIIB __IIIC __IVA __IVB __ Recurrent

Line of Treatment: __Neoadjuvant/Pre-Op __ Adjuvant/Post-Op __First Line __Second Line __Third Line __Third Line+

ECOG Performance Status: __ 0__ 1 __2 __3 __4

Biomarker:

RAS: __Wild type __Mutant

Adjuvant Therapy*

__Capecitabine (Xeloda)

__**FLOX**†: fluorouracil (5FU), leucovorin and oxaliplatin (Eloxatin)

__**FULV**: fluorouracil (5FU) and leucovorin

__**Modified FOLFOX-6**†: fluorouracil (5FU), leucovorin and oxaliplatin (Eloxatin)

Metastatic disease | RAS Wild Type (WT) or Mutant (MT)‡ | 1st or 2nd line therapy

__Capecitabine (Xeloda)

__**FOLFIRI:** fluorouracil (5FU), leucovorin, and irinotecan (Camptosar)

__**FOLFIRI:** fluorouracil (5FU), leucovorin, irinotecan (Camptosar), and bevacizumab (Avastin)

__**FOLFOXIRI:** fluorouracil (5FU), leucovorin, irinotecan (Camptosar), oxaliplatin (Eloxatin), and bevacizumab (Avastin)

__**FULV:** fluorouracil (5FU) and leucovorin

__**FULV:** fluorouracil (5FU), leucovorin and bevacizumab (Avastin)

__**Modified FOLFOX-6**: fluorouracil (5FU), leucovorin, and oxaliplatin (Eloxatin)

__**Modified FOLFOX-6:** fluorouracil (5FU), leucovorin, oxaliplatin (Eloxatin), and bevacizumab (Avastin)

Metastatic disease | RAS WT | 2nd line

__**FOLFIRI**: fluorouracil (5FU), leucovorin, irinotecan (Camptosar) and panitumumab (Vectibix)

__Irinotecan (Camptosar) and panitumumab (Vectibix)

Metastatic disease | RAS WT or MT‡ | 3rd line+

__Trifluridine + tipiracil (Lonsurf)

Metastatic disease | RAS WT | 3rd line+

__Irinotecan (Camptosar) and panitumumab (Vectibix)

__Panitumumab (Vectibix) monotherapy

*Patients with stage II MSI-H (microsatellite instability - high) colorectal cancer are not included in the Adjuvant Pathway.

†Dose & sequence of administration differ between modified FOLFOX-6 and FLOX

‡Exon 2 KRAS, non-exon 2 KRAS, and NRAS mutations

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Gastric, Esophageal, and Gastroesophageal Junction Cancer (Adenocarcinoma) Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __0 __IA __ IB __ IIA__IIB __IIIA__IIIB__IIIC __IV __Recurrent

Line of Treatment: __Neoadjuvant/Pre-Op __ Adjuvant/Post-Op __First Line __Second Line __Third Line __Third Line+

ECOG Performance Status: __ 0__ 1 __2 __3 __4

Is the patient going to have surgery? __Yes __No

Is the patient going to have radiation? __Yes __No

Primary therapy | Resectable and unresectable disease

__ Cisplatin (Platinol) and fluorouracil (5FU)

__ Fluorouracil (5FU) and cisplatin (Platinol) with concurrent radiation therapy (RT)

__ Paclitaxel (Taxol) and carboplatin (Paraplatin) with concurrent radiation therapy (RT)

Post-operative treatment

__ Fluorouracil (5FU) and leucovorin with concurrent radiation therapy (RT)

Recurrent/metastatic or locally advanced/inoperable disease | HER2 Negative | First line of therapy (1st line)

__ Cisplatin (Platinol) and fluorouracil (5FU)

__ Fluorouracil (5FU) and irinotecan (Camptosar)

__ **FLO / FOLFOX**: fluorouracil (5FU), leucovorin, and oxaliplatin (Eloxatin)

__ **FLP**: fluorouracil (5FU), leucovorin, and cisplatin (Platinol)

Recurrent/metastatic or locally advanced/inoperable disease | HER2 Positive | First line of therapy (1st line)

__ Cisplatin (Platinol), fluorouracil (5FU), and trastuzumab (Herceptin)

Recurrent/metastatic or locally advanced/inoperable disease | Second line of therapy (2nd line)

__ Irinotecan (Camptosar)

__ Paclitaxel (Taxol)

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Head and Neck Cancer Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __0 __I __II __III __IVA __IVB __IVC __Recurrent

Line of Treatment: __Neoadjuvant/Pre-Op __ Adjuvant/Post-Op __First Line __Second Line __Second Line+

ECOG Performance Status: __ 0__ 1 __2 __3 __4

Hypopharynx and larynx: candidate for local therapy (M0) | Primary systemic therapy & concurrent radiation therapy (RT)

__ High dose cisplatin (Platinol) * with concurrent radiation therapy (RT)

Hypopharynx and larynx: candidate for local therapy (M0) | Post-operative systemic therapy & concurrent radiation therapy (RT)

__ High dose cisplatin (Platinol)* with concurrent radiation therapy (RT)

Lip, oral cavity, oropharynx, ethmoid sinus, maxillary sinus, occult primary: candidate for local therapy (M0) | Primary systemic therapy & concurrent radiation therapy (RT)

__ High dose cisplatin (Platinol)* with concurrent radiation therapy (RT), followed by adjuvant therapy

Lip, oral cavity, oropharynx, ethmoid sinus, maxillary sinus, occult primary : candidate for local therapy (M0) | Post-operative systemic therapy & concurrent radiation therapy (RT)

__ High dose cisplatin (Platinol)* with concurrent radiation therapy (RT)

Nasopharynx: candidate for local therapy (M0) | Primary systemic therapy & concurrent radiation therapy (RT) followed by adjuvant therapy

__ High dose cisplatin (Platinol)* with concurrent radiation therapy (RT), followed by adjuvant therapy

Nasopharynx | Metastatic and recurrent disease | First Line and subsequent lines of therapy (1st line+) | Performance Status 0,1,2

__ Cisplatin (Platinol)** and fluorouracil (5FU)

__ Cisplatin (Platinol)** and gemcitabine (Gemzar)

__ Cisplatin (Platinol)** and paclitaxel (Taxol)

__ Cisplatin (Platinol) or carboplatin (Paraplatin) (single agent)

__ Gemcitabine (Gemzar)

__ Methotrexate

__ Paclitaxel (Taxol)

*High dose cisplatin is defined as weekly dosing to achieve 200-300 mg/m2 total cisplatin dose
**Substitution of carboplatin for cisplatin, and vice-versa, is acceptable for metastatic disease

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Head and Neck Cancer Pathways
(Continued)

Non-Nasopharyngeal (Squamous cell) | Metastatic and recurrent disease | First Line | Performance Status 0,1,2

__ Carboplatin (Paraplatin), fluorouracil (5FU), and cetuximab (Erbitux)

__ Cisplatin (Platinol), fluorouracil (5FU), and cetuximab (Erbitux)

Non-nasopharyngeal (Squamous cell) | Metastatic and recurrent disease | Second Line and Subsequent lines of therapy | Performance Status 0,1,2

__ Fluorouracil (5FU)

__ Methotrexate

__ Nivolumab (Opdivo)

__ Paclitaxel (Taxol)

*High dose cisplatin is defined as weekly dosing to achieve 200-300 mg/m2 total cisplatin dose
**Substitution of carboplatin for cisplatin, and vice-versa, is acceptable for metastatic disease

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Hodgkin Lymphoma Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __0 __0-E __0-X __0-XE __IA __IA-E __IA-X __IA-XE __IB __IB-E __IB-X __IB-XE __IIA __IIA-E __IIA_X __IIA-XE __IIB __IIB-E __IIB-X __IIB-XE __IIIA __IIIA-E __IIIA-X __IIIA-XE __IIIB __IIIB-E __IIIB-X __IIIB-XE __IVA __IVA-E __IVA-X __IVA-XE __IVB __IVB-E __IVB-X __IVB-XE __NS __Recurrent

Line of Treatment: __First Line __Second Line __Third Line __Third Line+ __Maintenance

ECOG Performance Status: __ 0__ 1 __2 __3 __4

Biomarker:

CD20 status: __Negative __Positive __Not reported

HIV associated lymphoma: __No __Yes

__ Transplant candidate __ Non-transplant candidate

Classical Hodgkin | Early or Late Stage | with or without Radiation Therapy (RT)

__**ABVD**: doxorubicin (Adriamycin), bleomycin (Blenoxane), vinblastine (Velban), and dacarbazine (DTIC)

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Kidney Cancer Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __0 __I __II __III __IV __Recurrent

Line of Treatment: __Adjuvant/Post-Op __First Line __Second Line __Third Line __Third Line +

ECOG Performance Status: __ 0__ 1 __2 __3 __4

Biomarker:

Prior therapy: _____

Renal cancer risk*: __Poor risk __Intermediate risk __Good risk

Metastatic | First line therapy (1st line) | Clear Cell and Non-clear Cell

__Pazopanib (Votrient)

__Sunitinib (Sutent)

__Temsirolimus (Torisel)

Metastatic | Second line therapy (2nd line) | Clear Cell

__Axitinib (Inlyta)

__Cabozantinib (Cabometyx)

__Nivolumab (Opdivo)

__Sorafenib (Nexavar)

*Risk factors (Good risk = no risk factors, Intermediate risk = 1 or 2 risk factors, Poor risk = 3 or more risk factors):

- High lactate dehydrogenase (LDH) level, greater than 1.5 times the upper limit of normal
- High blood calcium level, corrected level greater than 10 mg/dL
- Anemia
- 2 or more sites of organ metastasis
- Less than a year from original diagnosis to the need for systemic treatment
- Karnofsky performance status less than or equal to 70 (at least able to perform self-care activities, up and about greater than 50% of waking hours)

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

1023-0717

Lung Cancer: Non-Small Cell Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __IA__IB __IIA __IIB __IIIA __IIIB __IV __ Recurrent

Line of Treatment: __ Neoadjuvant/Pre-Op __Adjuvant/Post-Op __ First Line __Second Line __ Third Line __ Third Line+ __Maintenance

ECOG Performance Status: __ 0__ 1 __2 __3 __4

Biomarker:

ALK status: __Positive __Negative __Not reported

EFGR: __Mutation __Wild type __Not reported

BRAF: __V600E Mutation __ V600K Mutation __Wild type __Not reported

MET amplification: __Positive __Negative __Not reported

RET gene rearrangement: __Absent __Present __Not reported

ROS1 rearrangement: __Positive __Negative __Not reported

Adjuvant Therapy

__Cisplatin (Platinol) and vinorelbine (Navelbine)

__Gemcitabine (Gemzar) and cisplatin (Platinol)

__Paclitaxel (Taxol) and carboplatin (Paraplatin)

Primary Therapy for Locally Advanced/Unresectable | Stage III

__Paclitaxel (Taxol) (Q3Wks) and carboplatin (Paraplatin) with XRT

Metastatic disease | ALK+ or ROS1+ | First line (1st line)

__Crizotinib (Xalkori)

Metastatic disease |EGFR+ | First line (1st line)

__Afatinib (Gilotrif)

__Erlotinib (Tarceva)

Metastatic disease | Non-squamous | ECOG PS: 0, 1, 2 | First line (1st line)

__Carboplatin* (Paraplatin) and paclitaxel (Taxol)

__Cisplatin* (Platinol) and gemcitabine (Gemzar)

__Cisplatin* (Platinol) and pemetrexed (Alimta)

__Paclitaxel (Taxol) and carboplatin (Paraplatin) and bevacizumab (Avastin)

*Substitution of carboplatin (Paraplatin) for cisplatin (Platinol), and vice-versa, is allowed

** For patients with EGFR T790M mutation

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Lung Cancer: Non-small Cell Pathways
(continued)

Metastatic disease | Squamous | ECOG PS: 0, 1, 2 | First line (1st line)

__Carboplatin* (Paraplatin) and paclitaxel (Taxol)

__Cisplatin* (Platinol) and gemcitabine (Gemzar)

Metastatic disease | PD-L1 Positive | First Line (1st line)

__Pembrolizumab (Keytruda)

Metastatic disease | Non-squamous | ECOG PS: 0, 1, 2 | Maintenance

__Continuation bevacizumab (Avastin)

__Continuation pemetrexed (Alimta)

__Switch pemetrexed (Alimta)

Metastatic disease | ALK+ or EGFR+ | ECOG PS: 0, 1, 2 | Second line (2nd line) after targeted 1st line therapy

__Carboplatin* (Paraplatin) and paclitaxel (Taxol)

__Cisplatin* (Platinol) and gemcitabine (Gemzar)

__Cisplatin* (Platinol) and pemetrexed (Alimta)

Metastatic disease | EGFR T790M mutation | Second line (2nd line) after targeted 1st line therapy

__Osimertinib (Tagrisso)

Metastatic disease | Non-squamous | ECOG PS: 0, 1, 2 | Second line (2nd line)

__Docetaxel (Taxotere)

__Nivolumab (Opdivo)

__Pemetrexed (Alimta)

Metastatic disease | Squamous | ECOG PS: 0, 1, 2 | Second line (2nd line)

__Nivolumab (Opdivo)

*Substitution of carboplatin (Paraplatin) for cisplatin (Platinol), and vice-versa, is allowed
** For patients with EGFR T790M mutation

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Lung Cancer: Small Cell Lung Cancer Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __IA__IB __IIA __IIB __IIIA __IIIB __IV __ Recurrent

Line of Treatment: __ Neoadjuvant/Pre-Op __Adjuvant/Post-Op __ First Line __Second Line __ Third Line __ Third Line+ __Maintenance

ECOG Performance Status: __ 0__ 1 __2 __3 __4

Biomarker:

ALK status: __Positive __Negative __Not reported

EFGR: __Mutation __Wild type __Not reported

BRAF: __V600E Mutation __ V600K Mutation __Wild type __Not reported

MET amplification: __Positive __Negative __Not reported

RET gene rearrangement: __Absent __Present __Not reported

ROS1 rearrangement: __Positive __Negative __Not reported

Limited Stage | Primary, Adjuvant, or First Line Therapy (1st line)

__ Carboplatin (Paraplatin) and etoposide (Toposar) ± XRT

__ Cisplatin (Platinol) and etoposide (Toposar) ± XRT

Extensive Stage | First line of therapy (1st line)

__ Carboplatin (Paraplatin) and etoposide (Toposar)

Second and subsequent lines of therapy (2nd line +) | Relapse less than 6 months

__ Carboplatin (Paraplatin) and etoposide (Toposar)

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Melanoma Pathways: Metastatic Melanoma

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __0 __IA __IB __IIA __IIB __IIC __III __IV __Recurrent

Line of Treatment: __Adjuvant/Post-Op __First Line __Second Line __Third Line __Third Line +

ECOG Performance Status: __0 __1 __2 __3 __4

Biomarkers:

BRAF* status: __V600E Mutation positive__V600K Mutation positive __Wild Type (no mutation) __Not Reported

c-kit status: __Exon 11 Mutation Present __Exon 9 Mutation Present __No Mutation __Not Reported

Metastatic disease | First and subsequent lines of therapy (1st line +) | Any BRAF status | ECOG PS: 0, 1, 2

__ Pembrolizumab (Keytruda)*

Metastatic disease | First line of therapy (1st line) |BRAF mutated † | Symptomatic disease | ECOG PS: 0, 1, 2

__ Vemurafenib (Zelboraf) and cobimetinib (Cotellic)

Metastatic disease | Second and subsequent lines of therapy (2nd line +) | BRAF mutated † | ECOG PS: 0, 1, 2

__ Vemurafenib (Zelboraf) and cobimetinib (Cotellic)

Metastatic disease | Second and subsequent lines of therapy (2nd line +) | Any BRAF status| ECOG PS: 0, 1, 2

__ Ipilimumab (Yervoy)

* Administered at a dose of 2 mg/kg (up to a maximum of 200 mg).

† BRAF mutations include V600E and V600K mutations.

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Myeloma Pathways: Multiple Myeloma

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __New diagnosis __Relapse

Line of Treatment: __First Line __Second Line __Third Line __Third Line+ __Maintenance

ECOG Performance Status: __ 0__ 1 __2 __3 __4

Biomarker:

__ Transplant candidate __ Non-transplant candidate

Primary/ First line of therapy (1st line) | Transplant candidates

__ **VRD/VDR**: bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone

Primary/ First line of therapy (1st line) | Ineligible for transplant

__ **CyBorD or VDC**: bortezomib (Velcade), cyclophosphamide (Cytoxan), and dexamethasone

__ **R-dex**: lenalidomide (Revlimid) and low-dose dexamethasone

__ **VRD/VDR**: bortezomib (Velcade), lenalidomide (Revlimid) and dexamethasone

__ **VD**: bortezomib (Velcade) and dexamethasone

Maintenance therapy | Post-transplant

__ Lenalidomide (Revlimid)

Relapsed disease | Second and subsequent lines of therapy (2nd line+)

__ **CRd or KRd**: carfilzomib (Kyprolis), lenalidomide (Revlimid) and dexamethasone

__ **DRD:** daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone

__ **DVD:** daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone

Relapsed disease | Third and subsequent lines of therapy (3rd line+)

__ Daratumumab (Darzalex)

__ Elotuzumab (Empliciti), lenalidomide (Revlimid), and dexamethasone

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

NHL: Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Lymphoma Stage: __0 __0-E __0-X __0-XE __IA __IA-E __IA-X __IA-XE __IB __IB-E __IB-X __IB-XE __IIA __IIA-E __IIA-X __IIA-XE __IIB __IIB-E __IIB-X __IB-XE __IIIA __IIIA-E __IIIA-X __IIIA-XE __IIIB __IIIB-E __IIIB-X __IIIB-XE __IVA __IVA-E __IVA-X __IVA-XE __IVB __IVB-E __IVB-X __IVB-XE __NS __Recurrent

Leukemia Stage: __NS (No stage) __Recurrent

Line of Treatment: __First Line __Second Line __Third Line __Third Line+ __Maintenance

ECOG Performance Status: __0 __1 __2 __3 __4

Biomarkers:

11q deletion: __Absent __Present

17p deletion: __Absent __Present

CD20 Status: __Negative __Positive

TP53 Status: __Mutation Absent __Mutation Present

First Line Therapy (1st line) | with 17p Deletion

__ Ibrutinib (Imbruvica)

First Line Therapy (1st line) | without 17p Deletion

__FCR: fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (Rituxan)

__ Ibrutinib (Imbruvica)

__Obinutuzumab (Gazyva) and chlorambucil (Leukeran)

Second and subsequent lines of therapy (2nd line +) | with 17p Deletion

__Ibrutinib (Imbruvica)

__Idelalisib (Zydelig)

__Idelalisib (Zydelig) and rituximab (Rituxan)

Second and subsequent lines of therapy (2nd line +) | without 17p Deletion or Unspecified

__FCR: fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (Rituxan)

__ Ibrutinib (Imbruvica)

__Idelalisib (Zydelig)

__Idelalisib (Zydelig) and rituximab (Rituxan)

__Rituximab (Rituxan) and bendamustine (Bendeka, Treanda)

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

NHL: Diffuse Large B-Cell Lymphoma Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __0 __0-E __0-X __0-XE __IA __IA-E __IA-X __IA-XE __IB __IB-E __IB-X __IB-XE __IIA __IIA-E __IIA_X __IIA-XE __IIB __IIB-E __IIB-X __IIB-XE __IIIA __IIIA-E __IIIA-X __IIIA-XE __IIIB __IIIB-E __IIIB-X __IIIB-XE __IVA __IVA-E __IVA-X __IVA-XE __IVB __IVB-E __IVB-X __IVB-XE __NS __Recurrent

Line of Treatment: __First Line __Second Line __Third Line __Third Line+ __Maintenance

ECOG Performance Status: __ 0__ 1 __2 __3 __4

Biomarker:

CD20 status: __Negative __Positive

HIV associated lymphoma: __No __Yes

__ Transplant candidate __ Non-transplant candidate

First line of therapy (1st line)

__**R-CHOP (21)** : cyclophosphamide, doxorubicin (Adriamycin), vincristine (Vincasar), prednisone, and rituximab (Rituxan)

First line of therapy (1st line) | Contraindication to anthracycline

__**R-CEOP**: cyclophosphamide, etoposide (Toposar), vincristine (Vincasar), prednisone, and rituximab (Rituxan)

Second and subsequent lines of therapy (2nd line+) | Transplant candidates

__**R-GDP:** gemcitabine (Gemzar), dexamethasone, cisplatin, and rituximab (Rituxan) **OR**
__**R-GDP:** gemcitabine (Gemzar),dexamethasone, carboplatin, and rituximab (Rituxan)

__**R-ICE:** ifosfamide (Ifex), carboplatin, etoposide (Toposar), and rituximab (Rituxan)

Second and subsequent lines of therapy (2nd line +) | Non-Transplant candidates

__**BR**: bendamustine (Bendeka, Treanda) and Rituximab (Rituxan)

__**R-GDP:** gemcitabine (Gemzar), dexamethasone, cisplatin, and rituximab (Rituxan) **OR**
__**R-GDP:** gemcitabine (Gemzar),dexamethasone, carboplatin, and rituximab (Rituxan)

__**R-GemOx:** gemcitabine (Gemzar), oxaliplatin, and rituximab (Rituxan)

__Rituximab (Rituxan) monotherapy **reserved for frail patients or elderly patients**

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

NHL: Follicular and Marginal Zone Lymphoma Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __0 __0-E __0-X __0-XE __IA __IA-E __IA-X __IA-XE __IB __IB-E __IB-X __IB-XE __IIA __IIA-E __IIA-X __IIA-XE __IIB __IIB-E __IIB-X __IIB-XE __IIIA __IIIA-E __IIIA-X __IIIA-XE __IIIB __IIIB-E __IIIB-X __IIIB-XE __IVA __IVA-E __IVA-X __IVA-XE __IVB __IVB-E __IVB-X __IVB-XE __NS __Recurrent

Line of Treatment: __First Line __Second Line __Third Line __Third Line+ __Maintenance

ECOG Performance Status: __0 __1 __2 __3 __4

Biomarkers:

CD20 Status: __Positive __Negative

__ Transplant candidate __ Non-transplant candidate

Gastric MALT (Mucosa-associated Lymphoid Tissue) Lymphoma: Stage IE or IIE, *H. pylori* positive*

__ Antibiotic therapy for *H. pylori* eradication

Splenic Marginal Zone Lymphoma † OR Gastric MALT Lymphoma: First line of therapy (1st line)

__ Rituximab (Rituxan) monotherapy

Follicular (Grade I-IIIA) Lymphoma and other Marginal Zone Lymphomas | First line of therapy (1st line)

__ **BR**: Bendamustine (Bendeka, Treanda) and rituximab (Rituxan)

__ **R-CHOP(21)**: Cyclophosphamide, doxorubicin (Adriamycin), vincristine (Vincasar), prednisone, and rituximab (Rituxan)

__ **R-CVP**: Cyclophosphamide, vincristine (Vincasar), prednisone, and rituximab (Rituxan)

__ Rituximab (Rituxan) monotherapy

Follicular Lymphoma and other Marginal Zone Lymphomas | First line of therapy (1st line) | Additional options for the elderly or infirm

__ Chlorambucil (Leukeran)

__ Chlorambucil (Leukeran) and rituximab (Rituxan)

__ Cyclophosphamide

__ Cyclophosphamide and rituximab (Rituxan)

Follicular Lymphoma (Grade III) | First line of therapy (1st line)

__ **R-CHOP(21)**: Cyclophosphamide, doxorubicin (Adriamycin), vincristine (Vincasar), prednisone, and rituximab (Rituxan)

__ **R-CEOP**: Cyclophosphamide, etoposide (Toposar), vincristine (Vincasar), prednisone, and rituximab (Rituxan)

*Gastric MALT with translocation 11;18 (t11;18) (q21;q21) predicts a lower response rate to anti-*H.pylori* treatment. Radiation therapy or other local intervention may be indicated.

†Splenectomy is also a recommended option for Splenic Marginal Zone Lymphoma (NCCN 2A).

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

NHL: Mantle Cell Lymphoma Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __0 __0-E __0-X __0-XE __IA __IA-E __IA-X __IA-XE __IB __IB-E __IB-X __IB-XE __IIA __IIA-E __IIA_X __IIA-XE __IIB __IIB-E __IIB-X __IIB-XE __IIIA __IIIA-E __IIIA-X __IIIA-XE __IIIB __IIIB-E __IIIB-X __IIIB-XE __IVA __IVA-E __IVA-X __IVA-XE __IVB __IVB-E __IVB-X __IVB-XE __NS __Recurrent

Line of Treatment: __First Line __Second Line __Third Line __Third Line+ __Maintenance

ECOG Performance Status: __ 0__ 1 __2 __3 __4

Biomarker:

CD20 status: __Negative __Positive __Not reported

HIV associated lymphoma: __No __Yes

__ Transplant candidate __ Non-transplant candidate

First Line Therapy | Transplant Candidate

__**Alternating R-CHOP/R-DHAP:** cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine (Vincasar), prednisone, rituximab (Rituxan) alternating with dexamethasone, cisplatin (Platinol), cytarabine (Cytosar-U), and rituximab (Rituxan)

__**Nordic Regimen**: dose-intensified rituximab (Rituxan), cyclophosphamide (Cytoxan), vincristine (Vincasar), doxorubicin (Adriamycin), prednisone, alternating with rituximab (Rituxan), and high-dose cytarabine (Cytosar-U)

First Line Therapy | Ineligible for transplant (not ASCT Candidate)

__Bendamustine (Bendeka, Treanda) and rituximab (Rituxan)

Second and Subsequent Lines of Therapy

__Bendamustine (Bendeka, Treanda) and rituximab (Rituxan)

__Bortezomib (Velcade)

__**FCMR:** fludarabine (Fludara), cyclophosphamide (Cytoxan), mitoxantrone (Novantrone), and rituximab (Rituxan)

__Ibrutinib (Imbruvica)

__Lenalidomide (Revlimid) *

* Following ***two*** prior therapies, including bortezomib

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Ovarian Cancer Pathways

Patient Name: _____ Date of Birth: _____
Member Number: _____ Treatment Start Date: _____
ICD-10 Code: _____ **Pathology**: _____
Stage: __I __IA __IB __IIA __IIB __IIC __IIIA __IIIB __IIIC __IV __Recurrent
Line of Treatment: __Neoadjuvant/Pre-Op ___ Adjuvant/Post-Op __First Line __Second Line __Third Line __Third Line+ __Maintenance
ECOG Performance Status: __0 __1 __2 __3 __4
Biomarkers:
Germline BRCA 1? __Mutation Present __Not Reported __Wild Type (mutation absent)
Germline BRCA 2? __Mutation Present __Not Reported __Wild Type (mutation absent)
Platinum sensitive? † __Yes __No __Not Reported
Platinum-refractory or resistant? __Yes __No __Not Reported

Adjuvant Therapy | Stage IA/B (Grade 2 or 3) or IC (Grade 1-3)

__Carboplatin (Paraplatin)* and paclitaxel (Taxol)

__Carboplatin (Paraplatin)* and dose dense paclitaxel (Taxol)

Adjuvant or primary Therapy | Stage II, III, IV

__IV paclitaxel (Taxol), Intraperitoneal (IP) cisplatin (Platinol) and IP paclitaxel (Taxol)

__Carboplatin (Paraplatin)* and paclitaxel (Taxol)

__Carboplatin (Paraplatin)* and dose dense paclitaxel (Taxol)

Recurrent Disease | First or subsequent line of therapy (1st line+) | Platinum-sensitive†

__Carboplatin (Paraplatin)* and paclitaxel (Taxol)

__Carboplatin (Paraplatin)* and weekly paclitaxel (Taxol)

__Carboplatin (Paraplatin) and gemcitabine (Gemzar)

__Cisplatin (Platinol) and gemcitabine (Gemzar)

Recurrent Disease | Second or subsequent line of therapy (2nd line+) | Platinum resistant

__Bevacizumab (Avastin)

__Bevacizumab (Avastin) and paclitaxel (Taxol)

__Bevacizumab (Avastin) and topotecan (Hycamtin)

__Docetaxel (Taxotere)

__Gemcitabine (Gemzar)

__Liposomal doxorubicin (Doxil or Lipodox)

__Topotecan (Hycamtin)

__Vinorelbine (Navelbine)

__Weekly paclitaxel (Taxol)

*Substitution of carboplatin (Paraplatin) for cisplatin (Platinol), and vice-versa, is allowed.

†Platinum sensitive is defined as recurrence >6 months after prior platinum-based therapy

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Pancreatic Cancer (Adenocarcinoma) Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __0 __IA __IB __IIA __IIB __III __IV __Recurrent

Line of Treatment: __ Neoadjuvant/Pre-Op __ Adjuvant/Post-Op __First Line __Second Line __Third Line __Third Line+

ECOG Performance Status: __ 0__ 1 __2 __3 __4

Adjuvant Therapy

__ Capecitabine (Xeloda) and gemcitabine (Gemzar)

__ **FULV** : fluorouracil (5FU) and leucovorin

__ Gemcitabine (Gemzar) monotherapy

Locally Advanced/Unresectable and Metastatic Disease | First line of therapy (1st line) | ECOG Performance Status (PS) : 0, 1, 2

__ **FOLFIRINOX**: fluorouracil (5FU), leucovorin, irinotecan (Camptosar), and oxaliplatin

__ Gemcitabine (Gemzar)

__ Gemcitabine (Gemzar) and nab-paclitaxel (Abraxane)

Locally Advanced/Unresectable and Metastatic Disease | Second line of therapy (2nd line) | ECOG Performance Status (PS) : 0, 1, 2

__ **OFF**: Fluorouracil (5FU), leucovorin, and oxaliplatin

__ Gemcitabine (Gemzar) monotherapy

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Prostate Cancer (Adenocarcinoma) Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ **Pathology**: _____

Stage: __ I __ IIA __IIB __ III __ IV __ Recurrent

Line of Treatment: __Neoadjuvant/Pre-Op __Adjuvant/Post-Op __ First Line __Second Line __Third Line __Third Line+

ECOG Performance Status: __0 __1 __2 __3 __4

Biomarkers:

Castration-resistant: __ Yes __ No

Prostate Cancer Recurrence Risk: __Very Low __Low __Intermediate __High __Very High

Adjuvant Therapy | Post- prostatectomy | Lymph node positive (LN+)

Goserelin (Zoladex) 3.6 mg monthly or 10.8 mg q 3 mos. [1-2]

Leuprolide (Eligard/Lupron) 7.5mg q mos. or 22.5 mg q 3 mos. or 30mg q 4 mos. or 45mg q 6 mos. [1-2]

Triptorelin (Trelstar) 3.75 mg q mos. or 11.25 mg q 3 mos. or 22.5 q 6 mos. [1-2]

Intermediate risk | Primary treatment with radiation therapy (RT)

Goserelin* (Zoladex)* 3.6 mg monthly or 10.8 mg q 3 mos. [3,5]

Leuprolide (Eligard/Lupron)* 7.5mg q mos. or 22.5 mg q 3 mos. or 30mg q 4 mos. or 45mg q 6 mos. [3,5]

Triptorelin (Trelstar)* 3.75 mg q mos. or 11.25 mg q 3 mos. or 22.5 q 6 mos. [3,5]

High Risk (T3a or Gleason 8-10), Very High Risk (T3b-T4), and Locally Advanced Prostate Cancer (LN+) | Primary treatment with radiation therapy (RT)

Goserelin (Zoladex)* [4]

Histrelin (Vantas)* [4]

Leuprolide (Eligard/Lupron)* [4]

Triptorelin (Trelstar)* [4]

Recurrent and Metastatic disease |Hormone Sensitive

Docetaxel (Taxotere)** (q 3 wks) with Androgen Deprivation Therapy (ADT) [18]

Goserelin (Zoladex)** [6]

Histrelin (Vantas)** [6]

Leuprolide (Eligard/Lupron) ** [6]

Triptorelin (Trelstar)** [6]

*May be coadministered with bicalutamide (Casodex) or flutamide (Eulexin) for up to 30 days in patients who are at risk of developing symptoms associated with testosterone flare.

**ADT: histrelin (Vantas), goserelin (Zoladex), leuprolide (Eligard/Lupron), triptorelin (Trelstar)

AIM SpecialtyHealth

8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Prostate Cancer (Adenocarcinoma) Pathways (continued)

Recurrent and Metastatic Disease | Hormone Resistant | First and subsequent lines of therapy (1st Line+)

Abiraterone (Zytiga)** with continue ADT [8,12]

Degarelix (Firmagon) with bicalutamide (Casodex)[7]

Docetaxel (Taxotere)** (q3 wks) with continue ADT [10,18]

Goserelin (Zoladex) with bicalutamide (Casodex) [6,7]

Leuprolide (Eligard/Lupron) with bicalutamide (Casodex) [6,7]

Triptorelin (Trelstar) with bicalutamide (Casodex) [6,7]

Recurrent and Metastatic Disease | Hormone Resistant | Second and subsequent lines of therapy (2nd Line +)

Cabazitaxel (Jevtana)** with ADT [11]

Docetaxel (Taxotere)** rechallenge with ADT [20-21]

Enzalutamide (Xtandi)** with ADT [15]

Continued ADT ** with supportive care ± dexamethasone [13-14,22-24]

*May be coadministered with bicalutamide (Casodex) or flutamide (Eulexin) for up to 30 days in patients who are at risk of developing symptoms associated with testosterone flare.

**ADT: histrelin (Vantas), goserelin (Zoladex), leuprolide (Eligard/Lupron), triptorelin (Trelstar)

AIM SpecialtyHealth

8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Testicular (Germ Cell) Cancer Pathways

Patient Name: _____ Date of Birth: _____
Member Number: _____ Treatment Start Date: _____
ICD-10 Code: _____ **Pathology**: _____
Stage: __I __IA __IB __IIA __IIB __IIC __IIIA __IIIB __IIIC __IV __Recurrent
Line of Treatment: __Neoadjuvant/Pre-Op ___ Adjuvant/Post-Op __First Line __Second Line __Third Line __Third Line+ __Maintenance
ECOG Performance Status: __0 __1 __2 __3 __4
Biomarkers:
Platinum-refractory or resistant? __Yes __No __Not Reported

Seminoma | Stage II-IIIA | Primary Therapy

__**BEP**: bleomycin, etoposide (Toposar), and cisplatin

__**EP**: etoposide (Toposar) and cisplatin

Seminoma | Stage IIIB-C | Good Risk | and Metastatic Disease

__**BEP**: bleomycin, etoposide (Toposar), and cisplatin

Nonseminoma | Stage II-IIIA | Primary Therapy

__**BEP**: bleomycin, etoposide (Toposar), and cisplatin

__**EP**: etoposide (Toposar) and cisplatin

Nonseminoma | Stage IIIB-C | Primary Therapy

__**BEP**: bleomycin, etoposide (Toposar), and cisplatin

Nonseminoma | Adjuvant Therapy after RPLND*

__**EP**: etoposide (Toposar) and cisplatin

*RPLND: Retroperitoneal Lymph Node Dissection

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Uterine Cancer Pathways

Patient Name: _____ Date of Birth: _____
Member Number: _____ Treatment Start Date: _____
ICD-10 Code: _____ **Pathology**: _____
Stage: __I __IA __IB __IIA __IIB __IIC __IIIA __IIIB __IIIC __IV __Recurrent
Line of Treatment: __Neoadjuvant/Pre-Op ___ Adjuvant/Post-Op __First Line __Second Line __Third Line __Third Line+ __Maintenance
ECOG Performance Status: __0 __1 __2 __3 __4
Biomarkers:
Estrogen Receptor: __Positive __Negative
Progesterone Receptor: __Positive __Negative

Adjuvant Therapy | Stage III-IV or High Risk Histologies

__ Carboplatin and paclitaxel

Recurrent / Metastatic | First and Subsequent Lines of Therapy (1st line +)

__ Carboplatin and paclitaxel

__ Cisplatin and doxorubicin (Adriamycin)

AIM SpecialtyHealth

8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com